ASRM Responds to Supreme Court Mifepristone Decision

May 14, 2026

For Immediate Release

WASHINGTON, DC—While not a final decision, the American Society for Reproductive Medicine (ASRM) is pleased that the Supreme Court's ruling will allow patients continued access to mifepristone. ASRM President Dr. Robert E. Brannigan, MD, issued the following statement in response to the U.S. Supreme Court’s administrative stay in Louisiana v. Food and Drug Administration, which temporarily pauses a Fifth Circuit order that would reinstate in-person dispensing requirements for mifepristone nationwide:

“Mifepristone is safe, effective, and supported by decades of clinical evidence. The FDA’s rigorous, evidence-based review process exists to ensure that decisions about medications are grounded in science, data, and patient safety. The longstanding role of the FDA in evaluating the safety and efficacy of prescription medications should be respected, and courts should exercise caution when considering measures to override the agency’s expert judgment.

“Reinstating medically unnecessary in-person dispensing requirements would create confusion for patients and providers, restrict access to time-sensitive reproductive health care, and make care harder and more expensive to obtain, especially for patients already facing barriers to medical care. Limiting access to a safe, effective medication would increase delays and obstacles for patients seeking medical miscarriage or abortion care. ASRM urges the courts to respect scientific evidence, uphold the FDA’s longstanding authority, and protect patient access to safe, affordable, and evidence-based care.”